Syndrome of Inappropriate Secretion of Antidiuretic Hormone Caused by Carboplatin After Switching from Cisplatin in a Metastatic Urethral Cancer Patient

Yosuke Sugiyama; Taku Naiki; Masahiro Kondo; Keitaro Iida; Yuki Kondo; Yoshihiko Tasaki; Tomoya Kataoka; Asami Hotta; Takahiro Yasui; Kazunori Kimura

doi:10.1016/j.eucr.2017.02.001

Syndrome of Inappropriate Secretion of Antidiuretic Hormone Caused by Carboplatin After Switching from Cisplatin in a Metastatic Urethral Cancer Patient

Urol Case Rep. 2017 Mar 1:12:17-19. doi: 10.1016/j.eucr.2017.02.001. eCollection 2017 May.

Authors

Affiliations

¹ Department of Pharmacy, Nagoya City University Hospital, Nagoya, Japan.
² Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
³ Department of Clinical Pharmaceutics, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
⁴ Department of Endocrinology and Diabetes, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
⁵ Department of Pharmacy, Nagoya City University Hospital, Nagoya, Japan; Department of Clinical Pharmaceutics, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.

Abstract

There is no established chemotherapy regimen in metastatic primary urethral cancer (mPUC). The efficacy of a cisplatin (CDDP)-based regimen has been reported, however, when the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) occurs, the chemotherapy regimen should be changed to another platinum compound. In this report, we describe a 66-year-old woman who was diagnosed as mPUC with, CDDP-induced SIADH. After switching her to CBDCA and careful managing her sodium balance, three courses of the chemotherapy regimen were completed.

Keywords: Carboplatin; Cisplatin; SIADH; Urethral carcinoma.

Publication types

Case Reports